Subscribe to RSS
DOI: 10.1055/s-0033-1341498
Tolerability and Pharmacokinetics of Biapenem Following Single and Multiple Intravenous Administrations in Healthy Chinese Subjects: An Open-Label, Randomized, Single-Center Study
Publication History
received 09 January 2013
accepted 11 March 2013
Publication Date:
12 April 2013 (online)
![](https://www.thieme-connect.de/media/drugres/201308/lookinside/thumbnails/10.1055-s-0033-1341498-1.jpg)
Abstract
This study was designed to evaluate the tolerability and pharmacokinetics of biapenem after single and multiple intravenous administrations in healthy Chinese subjects. Subjects were randomly allocated to receive a single 0.15, 0.3, or 0.6 g dose of biapenem. Subjects assigned to the 0.3 g single dose group continued into the multiple-dose phase. Blood samples were collected over 6 h and plasma biapenem concentrations were determined by a validated HPLC method. Tolerability was assessed by monitoring vital signs, laboratory parameters, physical examinations, electrocardiogram, and adverse events collected by non-directive questioning/spontaneous reporting. Pharmacokinetic parameters for biapenem after intravenous administration of a single dose of 0.15, 0.3, or 0.6 g were as follows: Cmax=7.06 (1.30), 15.59 (1.33), and 29.12 (1.22) mg/L; AUC0–6 h=8.95 (1.33), 22.62 (1.25), and 42.05 (1.19) mg · h/L; t1/2=0.97 (0.13), 1.04 (0.08), and 1.12 (0.08) h; CL=15.78 (1.32), 12.91 (1.24), and 13.95 (1.19) L/h; Vd=21.87 (1.25), 19.31 (1.25), and 22.41 (1.23) L, respectively. Pharmacokinetic parameters for biapenem after intravenous administration of multiple 0.3 g doses were as follows: Cmax=18.50 (1.16) mg/L; AUC0–6 h=26.45 (1.15) mg · h/L; t1/2=1.06 (0.15) h; CL=11.06 (1.16) L/h; Vd=16.78 (1.19) L. The incidence of reported AEs was as follows: phlebitis (2/10), nausea (1/10), and diarrhea (1/10). All of the AEs were mild in intensity. The pharmacokinetic properties of biapenem were linear at dose of 0.15–0.6 g. All biapenem doses appeared to be well tolerated.
-
References
- 1 Perry CM, Ibbotson T. Biapenem. Drugs 2002; 62: 2221-2234
- 2 Kikuchi E, Kikuchi J, Nasuhara Y et al. Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions. Antimicrob Agents Chemother 2009; 53: 2799-2803
- 3 Hara T, Araake M, Watabe H. Antibacterial activity of biapenem against recent clinical isolates (in Japanese). Jpn J Antibiot 2003; 56: 138-141
- 4 Ubukata K, Hikida M, Yoshida M et al. In vitro activity of LJC10, 627, a new carbapenem antibiotic with high stability to dehydropeptidase I. Antimicrob Agents Chemother 1990; 34: 994-1000
- 5 Hikida M, Kawashima K, Nishiki K et al. Renal dehydropeptidase-I stability of LJC10, 627, a new carbapenem antibiotic. Antimicrob Agents Chemother 1992; 36: 481-483
- 6 Papp-Wallace KM, Endimiani A, Taracila MA et al. Carbapenems: past, present, and future. Antimicrob Agents Chemother 2011; 55: 4943-4960
- 7 Jia B, Lu P, Huang W et al. A multicenter randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Chemotherapy 2010; 56: 285-290
- 8 Nakagawa Y, Suzuki K, Hirose T et al. Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study. J Infect Chemother 2011; 17: 58-67
- 9 Matsumoto F, Inoue M, Sakurai I et al. A comparative study of biapenem and imipenem/cilastatin in lower respiratory infections [in Japanese]. Jpn J Chemother 2000; 48: 45-67
- 10 Muto Y, Mikami Y, Sakakibara S et al. Pharmacokinetic and pharmacodynamic properties of biapenem, a carbapenem antibiotic, in rat experimental model of severe acute pancreatitis. Pancreas 2008; 36: 125-132
- 11 Fujimura S, Nakano Y, Sato T et al. Relationship between the usage of carbapenem antibiotics and the incidence of imipenem-resistant Pseudomonas aeruginosa. J Infect Chemother 2007; 13: 147-150
- 12 El-Gamal MI, Oh CH. Current Status of Carbapenem Antibiotics. Curr Top Med Chem 2010; 10: 1882-1897
- 13 Matsumoto F, Imai T, Sakurai I et al. A comparative study of biapenem and imipenem/cilastatin for chronic respiratory tract infections [in Japanese]. Jpn J Chemother 1995; 43: 63-84
- 14 Bassetti M, Nicolini L, Esposito S et al. Current status of newer carbapenems. Curr Med Chem 2009; 16: 564-575
- 15 Zhao L, Liu Y, Kou Z et al. Improved RP-HPLC method to determine biapenem in human plasma/urine and its application to a pharmacokinetic study. Arzneimittelforschung 2011; 61: 197-204
- 16 Koeppe P, Hoffler D, Fitzen B. Biapenem pharmacokinetics in healthy volunteers and in patients with impaired renal function. Arzneimittelforschung 1997; 47: 1250-1256
- 17 Kozawa O, Uematsu T, Matsuno H et al. Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects. Antimicrob Agents Chemother 1998; 42: 1433-1436
- 18 Mouton JW, Touzw DJ, Horrevorts AM et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000; 39: 185-201
- 19 Tarao F, Miura T, Saito A et al. Pharmacokinetic study of biapenem [in Japanese]. Jpn J Chemother 1996; 44: 769-775
- 20 Nakashuma M, Uematsu T, Ueno K et al. Phase I study of L-627, biapenem, a new parenteral carbapenem antibiotic. Int J Chin Pharmacol Ther Toxicol 1993; 31: 70-76
- 21 World Medical Association. Declaration of Helsinki-ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html; Accessed May 4, 2012
- 22 European Medicine Agency. ICH Topic E 6 (R1): Guideline for Good Clinical practice. http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf Accessed May 4, 2012
- 23 State Food and Drug Administration. Guidance for clinical pharmacokinetics studies of chemical drugs [in Chinese]. http:www.sda.gov.cn./gsz0516/07.pdf Accessed May 4, 2012
- 24 Watanabe A, Fujimura S, Kikuchi T et al. Evaluation of dosing designs of carbapenems for severe respiratory infection using Monte Carlo simulation. J Infect Chemother 2007; 13: 332-340
- 25 Mikamo H, Tanaka K, Watanabe K. Efficacy of injectable carbapenems for pespiratory infections caused by streptococcus pneumoniae and haemophilus influenzae with monte carlo simulation [in Japanese]. Jpn J Antibiot 2007; 60: 47-57
- 26 Kayo I, Kazuro I, Aki I et al. A simple and rapid determination of biapenem in plasma by high-performance liquid chromatography. J Chromatogr B 2006; 844: 148-152
- 27 Liu Y, Huang J, Liu J et al. A simple and sensitive liquid chromatographic technique for the determination of cefotetan disodium in human plasma and its application in a pharmacokinetic study. J Huazhong Univ Sci Technolog Med Sci 2012; 32: 779-784
- 28 US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: Bioanalytical method validation. May 2001 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf; Accessed May 4, 2012
- 29 Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. 4th ed. Philadelphia, Baltimore: Williams & Wilkins; 2010
- 30 Chen ZY, Zheng QS, Sun RY. Functions of the DAS software for pharmacological calcution. Chin J Clin Pharmacol Ther 2002; 7: 562-564
- 31 Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. 4th ed. Stockholm, Sweden: Swedish Pharmaceutical Press; 2007
- 32 Shi S, Liu Y, Wu J et al. Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. Clin Ther 2010; 32: 1977-1986
- 33 Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10
- 34 Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36 (Suppl. 01) S42-S50
- 35 Takata T, Aizawa K, Shimizu A et al. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. J Infect Chemother 2004; 10: 76-85
- 36 Gomi K, Fujimura S, Fuse K et al. Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in the northeastern region of Japan in 2007. J Infect Chemother 2011; 17: 200-206
- 37 Liu W, Wang Y, Liu Y et al. In vitro antimicrobial activity of three carbapenems including biapenem [in Chinese]. Chin J Infect Chemother 2010; 10: 468-471